Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2022 Publisher: Aspire Pharma Ltd, Unit 4, Rotherbrook Court, Bedford Road, Petersfield, Hampshire, GU32 3QG, UK
Eyreida 0.3mg/ml eye drops, solution.
| Pharmaceutical Form |
|---|
|
Eye drops, solution. Clear, colourless, eye drops. Osmolality: 261-319 mOsm/Kg pH: 6.8–7.8. |
1 ml of solution contains 0.3mg of bimatoprost.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Bimatoprost |
Bimatoprost is a potent ocular hypotensive agent. It is a synthetic prostamide, structurally related to prostaglandin F2α (PGF2α), that does not act through any known prostaglandin receptors. |
| List of Excipients |
|---|
|
Sodium chloride |
Eyreida is presented as a clear, colorless aqueous solution in a white opaque 5 ml LDPE bottle and white Novelia nozzle (HDPE and silicone) and sealed with a white HDPE cap.
The following pack sizes are available: cartons containing 1 or 3 bottles of 3 ml solution.
Not all pack sizes may be marketed.
Aspire Pharma Ltd, Unit 4, Rotherbrook Court, Bedford Road, Petersfield, Hampshire, GU32 3QG, UK
PL35533/0107
Date of first authorisation: 18/12/2017
| Drug | Countries | |
|---|---|---|
| EYREIDA | Ireland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
